Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 0.90 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.90 |
| ▸ | GHSR | Q92847 | 1/20 | 0.90 |
| ▸ | TUBB4A | P04350 | 14/20 | 0.86 |
| ▸ | TUBB | P07437 | 14/20 | 0.86 |
| ▸ | TUBA3C | P0DPH7 | 14/20 | 0.86 |
| ▸ | TUBA1B | P68363 | 14/20 | 0.86 |
| ▸ | TUBA4A | P68366 | 14/20 | 0.86 |
| ▸ | TUBB4B | P68371 | 14/20 | 0.86 |
| ▸ | TUBB3 | Q13509 | 14/20 | 0.86 |
| ▸ | TUBB2A | Q13885 | 14/20 | 0.86 |
| ▸ | TUBB8 | Q3ZCM7 | 14/20 | 0.86 |
| ▸ | TUBA3E | Q6PEY2 | 14/20 | 0.86 |
| ▸ | TUBA1A | Q71U36 | 14/20 | 0.86 |
| ▸ | TUBA1C | Q9BQE3 | 14/20 | 0.86 |
| ▸ | TUBB6 | Q9BUF5 | 14/20 | 0.86 |
| ▸ | TUBB2B | Q9BVA1 | 14/20 | 0.86 |
| ▸ | TUBB1 | Q9H4B7 | 14/20 | 0.86 |
| ▸ | MEN1 | O00255 | 5/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desacetylvinblastinehydrazide SCHEMBL29376353 | 1.00 | MLNR (0.90) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Desacetylvinblastinehydrazide SCHEMBL15233643 | 1.00 | MLNR (0.90) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Desacetylvinblastinehydrazide SCHEMBL17529277 | 1.00 | MLNR (0.90) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Desacetylvinblastinehydrazide SCHEMBL13228849 | 1.00 | MLNR (0.90) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| Desacetylvinblastinehydrazide SCHEMBL15507828 | 1.00 | MLNR (0.90) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| SCHEMBL18602043 | 0.96 | MLNR (0.91) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| SCHEMBL18602221 | 0.96 | MLNR (0.91) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| SCHEMBL18602222 | 0.96 | MLNR (0.90) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| SCHEMBL19443227 | 0.96 | MLNR (0.90) | MLNRPTGS2KCNH2GHSRTUBB4A | |
| SCHEMBL19787808 | 0.96 | MLNR (0.90) | MLNRPTGS2KCNH2GHSRTUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485179-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250237656-A1 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2025-07-24 | — | — | US | disclosed |
| EP-4479748-A1 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | F. Hoffmann-La Roche AG (CH) | 2024-12-25 | — | — | EP | disclosed |
| EP-4267961-A1 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | F. Hoffmann-La Roche AG (CH) | 2023-11-01 | — | — | EP | disclosed |
| US-20230333095-A1 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023156510-A1 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-24 | — | — | WO | disclosed |
| US-20220273803-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2022-09-01 | — | — | US | disclosed |
| WO-2022136234-A1 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-30 | — | — | WO | disclosed |
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3971227-A1 | POLYMER, METHOD FOR PRODUCING POLYMER, AND DRUG CONJUGATE | Kawasaki Institute of Industrial Promotion (JP) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | MLNR 6/4885PTGS2 2992/4885KCNH2 2699/4885 |
| US-12485179-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | MLNR 6/4885PTGS2 2992/4885KCNH2 2699/4885 |
| US-20230333095-A1 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | ENTPD5, KLK3, GUSB | MLNR 4332/4885PTGS2 4815/4885KCNH2 4331/4885 |
| US-20220273803-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | MLNR 6/4885PTGS2 2992/4885KCNH2 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.